At a glance
- What the study gets you
- Health checks and monitoring — no treatment given
- Type of study
- Observational (no treatment given)
- Time in hospital
- In-person visits at study sites — visit count not specified by the sponsor
- Drug or intervention
- Not specified by the sponsor
- How long the study runs
- Study runs about 215 months (dates as stated)
- About the drug or intervention
- Not specified by the sponsor
- Patient visit burden
- Not specified by the sponsor
- Type of study
- Observing health over time
- Ages
- 40 Years to 100 Years
- Who
- All
- Number of participants
- 300
- Started
- 2009-01
- Last checked
- 2022-06
Plain English Summary
What is this study?
- • Testing a new treatment for pulmonary disease, chronic obstructive
- • Clinical study - 300 participants
- • The London COPD exacerbation (EXCEL) cohort builds on an established cohort started in 1995 and designed to study COPD exacerbations and their impact on health-status and disease progression
Who can take part?
- • Ages 40 Years to 100 Years
- • Diagnosed with pulmonary disease, chronic obstructive
Where?
- • London - National Heart and Lung Institute, Imperial College
This is a simplified summary. Always discuss with your doctor before making any decisions.
About This Trial
The London COPD exacerbation (EXCEL) cohort builds on an established cohort started in 1995 and designed to study COPD exacerbations and their impact on health-status and disease progression.
More detail
Our intentions are to phenotype Chronic Obstructive Pulmonary Disease (COPD) patients on the basis of factors that a related to (a) exacerbation frequency which will include (b) lung function to assess disease severity, (c) baseline therapy, (d) airway and systemic inflammatory markers, (e) health status, (f) gene expression, (g) airway bacterial and viral load and (h) co-morbidity including cardiovascular disease, diabetes and psychological disease, (i) psychological factors,(j) mortality, (k) nasal susceptibility to rhinovirus infection, (l) heart rate variability (m) exhaled hydrogen sulphide.
How this trial compares with your answers
Answer 2 more questions to improve match
What we know so far
Still need:
- • Tell us your age for better matching
- • Tell us your sex for better matching
Preliminary match based on your answers. Full eligibility requires on-site assessment including medical history, physical exam, and lab tests. This does not guarantee enrolment.
Eligibility at a Glance
Key info
- Age: 40 Years - 100 Years
- Who can join: All genders
What the study is looking for
- ✓Forced Expiratory Volume in 1 sec (FEV1)/Forced Vital Capacity (FVC) ratio of \<0.70
- ✓Able and willing to give informed and written consent
Who cannot take part
- ✗Patients with a history of asthma, bronchiectasis, carcinoma of the bronchus, or other significant respiratory...
- ✗Patients on Immunosuppressive medications or with active cancer
- ✗Long term steroid therapy
- ✗Age \<40 years at recruitment
See the full criteria
Where Is This Study? (1 UK site)
National Heart and Lung Institute, Imperial College
London SW3 6LR, United Kingdom
How to Get in Touch
Jadwiga A Wedzicha, MD
Sponsor contactCONTACT
Gavin C Donaldson, PhD
Sponsor contactCONTACT